Back
Vascular access for hemodialysis is essential for end-stage renal disease (ESRD). The process of creation, maintenance and treatment of complications in autologous (native) arteriovenous fistula (nAVF) is a multidisciplinary challenge. The access to renal replacement therapy (RRT) has been improved with the strengthening of multidisciplinary teams for vascular access planning; there is a risk that once vascular access is created, a diagnosis of nAVF failure of 5-30% for distal nAVF and 15-20% for proximal nAVF will occur.
A retrospective case-control analytical study was carried out with 71 patients on hemodialysis with a diagnosis of nAVF failure and 71 patients who did not present vascular access failure, treated in 3 Nephrology Centers during 2022. Analysis was performed in a 1:1 ratio, using SPSS 26.0 statistics package using two logistic regression models: univariate and multivariate, an nAVF survival model and implementation of indicators.
Factors such as diabetes and excess UF are associated with nAVF failure, generating an impact on the overall survival of nAVF in the Nephrology Centers of SERMESA, Nicaragua, based on international indicators of vascular access (GEMAV recommendations).